三叶草生物-B已正式启动针对RSV(呼吸道合胞病毒)、HMPV(人偏肺病毒)及可选PIV3(副流感3型病毒)的联合呼吸道候选疫苗的II期临床试验。该试验旨在评估这款多价疫苗的安全性与免疫原性,标志着公司在创新疫苗研发领域迈出关键一步。
三叶草生物-B已正式启动针对RSV(呼吸道合胞病毒)、HMPV(人偏肺病毒)及可选PIV3(副流感3型病毒)的联合呼吸道候选疫苗的II期临床试验。该试验旨在评估这款多价疫苗的安全性与免疫原性,标志着公司在创新疫苗研发领域迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.